Sponsor:
Trevi Therapeutics
Code:
NCT07946575
Conditions
Healthy Participants
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Accepted
Interventions
NAL ER
Quinidine Sulfate
Brief summary:
Conditions
Healthy Participants
Study ID
NCT07946575
Start date
Nov 3, 2026
Status verified date
Nov, 2026
Completion date
Dec, 2026
Anticipated
Primary completion date
Nov 30, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Accepted
Enrollment
30 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: NAL ER and Quinidine
Interventions
NAL ER
Quinidine Sulfate
Primary outcome measure
Central contacts
Locations
Clinical Pharmacology of Miami, LLC
Recruiting
Miami, Florida, United States, 33172
Sponsor
Trevi Therapeutics
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Trevi Therapeutics on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.